Driving Simulation Studies to Assess Cognitive Impairment
The FDA requires that all new drugs be evaluated for adverse effects on the central nervous system during first-in-human (FIH) studies. If adverse effects are observed, such as somnolence, further clinical trials must be conducted with the addition of cognitive test batteries.
In collaboration with Cognitive Research Corporation (CRC), Altasciences designs and conducts specialized driving studies. Watch our experts explain in more detail.